Cover Image
市場調查報告書

三次元細胞培養 (3D培養細胞) 市場:2015∼2025年

3D Cell Culture Market, 2015 - 2025

出版商 ROOTS ANALYSIS 商品編碼 332052
出版日期 內容資訊 英文 241 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
三次元細胞培養 (3D培養細胞) 市場:2015∼2025年 3D Cell Culture Market, 2015 - 2025
出版日期: 2015年05月28日 內容資訊: 英文 241 Pages
簡介

目前已有許多上市的三次元細胞培養系統(3D培養細胞系統)用於各種研究上。癌症研究是目前最穩定的應用領域,佔三次元細胞培養市場的40%。此外藥物·毒性篩檢也有35%的佔有率,相當受到注目。

本報告提供三次元細胞培養系統概要與2025年前的發展預測,彙整應用領域,及參與企業簡介等資料。

第1章 序論

第2章 摘要整理

第3章 簡介

  • 本章概要
  • 細胞培養的分類
  • 培養的細胞的形態
  • 細胞培養流程
  • 細胞培養的需求
  • 細胞培養的基本必要條件
  • 二次元到三次元的轉變
  • 三次元細胞培養的概念
  • 三次元細胞培養的優點與限制

第4章 細胞培養的分類

  • 細胞培養的分類:概要
  • Scaffold-based三次元培養
  • 非Scaffold-based三次元培養

第5章 三次元矩陣結構

  • 本章概要
  • 多孔支架製造方法
  • 纖維支架製造方法
  • 水凝膠製造方法
  • 自訂支架/即時試製/固體自由形態(SFF)技術
  • 微球體製造方法
  • 天然支架製造方法

第6章 三次元培養市場環境

  • 本章概要
  • 三次元培養系統市場概要
  • 支架格式有莫大貢獻
  • 無支架系統蔓延
  • 製造商:各地區預測
  • 其他的消耗品
  • 服務

第7章 癌症研究上三次元細胞培養的應用

  • 本章概要
  • 癌症研究導入三次元培養系統的理由
  • 透過三次元培養系統改善癌症藥物篩檢
  • 腫瘤學所採用的三次元培養模式

第8章 藥物·毒性篩檢的三次元細胞培養的應用

  • 本章概要
  • 藥物篩檢
  • 毒性研究的三次元細胞培養的應用
  • 毒性研究所採用的培養系統

第9章 幹細胞研究的三次元細胞培養的應用

  • 本章概要
  • 幹細胞分化上三次元細胞培養的應用
  • 為了引起胚狀體形成的in vitro三次元宏觀環境
  • 幹細胞的器官形成
  • 幹細胞研究的三次元細胞培養

第10章 市場規模與預測

  • 本章概要
  • 預測方法
  • 整體市場
  • 各零件
  • 各地區
  • 各用途
  • 三次元系統別

第11章

  • 本章概要
  • Corning Life Sciences
  • Life Technologies
  • Sigma Aldrich
  • Insphero
  • 3D Biotek
  • Reinnervate
  • Synthecon
  • Neuromics
  • Cosmo Bio

第12章 結論

第13章 採訪原稿

第14章 表格資料

第15章 附錄2:企業·組織清單

圖表

圖表

目錄
Product Code: RA10040

The concept of growing tissues outside their natural system in an artificially created microenvironment is known as tissue culturing. It is a common tool for developing model systems that are useful for studying the basic human molecular and cell biology metabolisms. Cell culturing was first initiated in flat plastic or glass dishes as 2D cell culturing. Since then, all the tissue engineering, stem cell, molecular biology work is being carried out on the widely popular petri dishes. However, there are several limitations associated with 2D cell culture that hamper the morphology, growth rate, cell function, viability and the overall behaviour of the cell as compared to the natural environment. As a result, 2D cell culture is not efficient for studying complex molecular metabolisms.

To carry out studies in vitro, cells have to be supplemented with an environment that is a close replica of the natural environment. This can be accomplished by using 3D cell cultures which are physiologically more relevant as compared to the 2D cell cultures. Cells in a 3D culture form natural cell to cell interactions and synthesize extracellular material as they do in in vivo. These cells exert forces on each other, moving and migrating as they do in natural environment. In addition, the interactions between them include gap junctions that facilitate exchange of ions, electrical currents and small molecules enhancing the signalling and communication between them. Such a close representation of the natural system in vitro gives insights about the behaviour of the cell when stimulated with a potential drug or a chemical.

Presently, there are several scaffold-based and scaffold-free 3D systems in the market that are widely being used for the purpose of research in a variety of application areas. Although 2D cultures are still more prominent, the encouraging results of 3D cultures have motivated researchers across the world to gradually transition to 3D cultures systems.

Synopsis

The '3D Cell Culture Market, 2015-2025' report provides an extensive study on the marketed 3D cell culture systems and those under development. There are a number of 3D cell culture systems that are already commercially available. However, these systems are primarily being used in a variety of research applications; therapeutic applications are still being explored. In addition, there are several promising 3D culture systems which are currently being developed worldwide; the approach is likely to result in many commercial success stories in the foreseen future. The report covers various aspects, such as, key players in the industry, 3D culture products in various biomedical applications and upcoming opportunities for several stakeholders.

As pharmaceutical companies continue to expand their research programs in this area, one of the key objectives outlined for this report is to understand the current and future potential of the market. This is done by analysing current trends in the wider cell culture market and the specific parameters which are likely to influence evolution of 3D cultures during the same time period. In addition, we have provided our outlook on the sub-market evolution of 3D culture instruments, 3D culture related consumables, 3D culture services and other biomaterials. We have also reviewed, in detail, the likely contribution to be made by different applications areas such as cancer research, drug and toxicity screening, stem cell research and regenerative medicines. The report also provides a snapshot of the likely evolution of the market across key geographies (US, EU and Asia).

To address the uncertainties in the market, we have provided three market forecast scenarios for the time period 2015 - 2025. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. Our opinions and insights, presented in this study, were influenced by the discussions that we conducted with experts in this area. All actual figures have been sourced and analysed from publicly available information and discussions with industry experts. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1.With a highly extensive classification, we have identified close to 150 3D culture systems. Of the two broad categories of scaffold-based and scaffold-free systems, scaffold-based systems are more popular, representing 76% of the 3D culture systems.
  • 2.Cancer research is currently the most well established application area and accounts for 40% of the present 3D culture market. Drug and toxicity screening have also emerged quite popular with 35% of the current market share.
  • 3.Stem cells and regenerative medicine together capture a share of 25% in the current 3D culture market and would gradually gain focus as the market matures in the field of therapeutics.
  • 4.Owing to the large life science market, the US holds maximum share (over 50%) of the current 3D culture market; EU, considered to be an early adopter, occupies around 30% of the current market. With increasing popularity of 3D culture systems, regions such as Asia and other countries of the world are also likely to start adopting 3D culture systems more aggressively.
  • 5.We expect the 3D culture market to be multi-billion dollar market by 2025, representing a healthy annual growth rate of 28%. As a result of this transition, we anticipate 3D cultures to capture 35% of the overall cell culture market in the next 10 years.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on where the 3D culture market is headed in the mid to long term.

Chapter 3 provides a general introduction to the 3D culture systems. In this section, we have briefly discussed the different types of cell cultures, conventional methods of cell culturing and various application domains. The chapter outlines a comparative analysis of 2D versus 3D cultures, focussing on the need and the advantages of 3D culture systems.

Chapter 4 gives an overview of the classification of 3D culture systems. It highlights the different approaches under the two broad categories of scaffold-based and scaffold-free 3D culture systems. We have discussed, in detail, the underlying concept, advantages and disadvantages of each sub-category of the two aforementioned strategies.

Chapter 5 summarises the different techniques deployed to fabricate various 3D matrices. It talks about the principle, merits and demerits associated with these methods. It also covers the key takeaways of several research studies carried out using these matrices.

Chapter 6 provides a comprehensive list of 3D culture systems. The list includes information on the 3D culture types and their respective sub-categories. We have also mapped the geographical presence of 3D culture systems. In addition, the chapter talks about other companies which provide 3D related services and associated consumables.

Chapter 7 provides applications of 3D culture systems in the field of cancer research. In addition, the chapter provides a holistic view on the various 3D culture products that have a key role to play in this domain.

Chapter 8 highlights the applications of 3D cultures in drug and toxicity screening. It elaborates on the liver models that can be utilised in toxicity and drug screening studies. The chapter also provides details on the 3D culture systems that have been deployed for this application.

Chapter 9 provides an overview of the 3D culture systems in the field of stem cell research. It highlights the scope of 3D culture approach in embryoid body formation and organogenesis. The chapter enlists and provides details of the 3D culture systems that have been used for the purpose of stem cell research.

Chapter 10 presents the detailed forecast for the 3D culture market segmented by type of 3D components, type of 3D system, type of applications and key geographies. Due to the uncertain nature of the market, we have presented three different growth tracks outlined as conservative, base and optimistic scenarios.

Chapter 11 provides detailed company profiles of the leading players in the market. Each company profile includes information such as financial performance, product portfolio, recent collaborations and future outlook.

Chapter 12 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 13 is a collection of interview transcript(s) of the discussions which were held during the course of this study.

Chapter 14 is an appendix which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix which provides the list of companies mentioned in the report

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Classification of Cell Cultures
    • 3.2.1. Primary Cell Cultures
    • 3.2.2. Secondary Cell Cultures
    • 3.2.3. Cell Lines
  • 3.3. Morphology of Cells in Culture
  • 3.4. Process for Obtaining Cell Culture
    • 3.4.1. Isolating Cells From Tissues
    • 3.4.2. Maintaining Cells in Culture
    • 3.4.3. Plating Density and Sub-Culturing
    • 3.4.4. Cryogenic Storage
    • 3.4.5. Issue of Cross-Contamination
  • 3.5. The Need of Cell Culturing
    • 3.5.1. Model Systems
    • 3.5.2. Drug Screening and Pharmacological Testing
    • 3.5.3. Cancer Research and Drug Discovery
    • 3.5.4. Virology
    • 3.5.5. Genetic Engineering and Gene Therapy
  • 3.6. Basic Requirements for Cell Culture
    • 3.6.1. Cell Culture Facility And Safety
    • 3.6.2. Avoiding Contamination
    • 3.6.3. Cell Culture Health And Optimal Conditions
  • 3.7. Transition From 2D To 3D Cell Culture
  • 3.8. The Concept of 3D Cell Culture
    • 3.8.1. What is Extra Cellular Matrix (ECM)?
    • 3.8.2. In Vitro Cell Culture
  • 3.9. Advantages and Limitations of 3D Cell Culture

4. CLASSIFICATION OF 3D CULTURE METHODS

  • 4.1. 3D Culture Classification: An Overview
  • 4.2. Scaffold-based 3D Cultures
    • 4.2.1. Hydrogels Or ECM Analogs
    • 4.2.2. Solid Scaffolds
    • 4.2.3. Micropatterned Surfaces
    • 4.2.4. Microfluidic Surfaces
    • 4.2.5. Microcarriers
  • 4.3. Scaffold-Free 3D Cultures
    • 4.3.1. Attachment Resistant Cell Surfaces
    • 4.3.2. Suspension Cultures

5. 3D MATRIX FABRICATION

  • 5.1. Chapter Overview
  • 5.2. Methods for Fabricating Porous Scaffolds
    • 5.2.1. Particulate Leaching
    • 5.2.2. Solvent Casting
    • 5.2.3. Emulsion Templating
    • 5.2.4. Gas Foaming
    • 5.2.5. Melt Molding
    • 5.2.6. Microsphere Sintering
  • 5.3. Methods for Fabricating Fibrous Scaffolds
    • 5.3.1. Fiber Mesh
    • 5.3.2. Fiber Bonding
    • 5.3.3. Electro Spinning
    • 5.3.4. Phase Separations
    • 5.3.5. Self Assembly
  • 5.4. Methods for Fabricating Hydrogels
    • 5.4.1. Solvent Casting And Particulate Leaching
    • 5.4.2. Gas Foaming
    • 5.4.3. Freeze Drying
    • 5.4.4. Co-Polymerisation / Crosslinking Methods
    • 5.4.5. Microfluidics
  • 5.5. Methods for Fabricating Custom Scaffolds / Rapid Prototyping / Solid Free-Form (SFF) Technique
    • 5.5.1. Stereo-Lithography
    • 5.5.2. 3D Printing And Organ Printing
    • 5.5.3. Selective Laser Sintering (SLS)
    • 5.5.4. Fused Deposition Modeling
    • 5.5.5. Membrane Lamination
  • 5.6. Methods for Fabricating Microspheres
    • 5.6.1. Solvent Evaporation
    • 5.6.2. Single and Double Emulsification Technique
    • 5.6.3. Particle Aggregated Scaffold
  • 5.7. Methods for Fabricating Native Scaffolds
    • 5.7.1. Decellularisation

6. 3D CULTURE MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. 3D Culture System Market Overview
  • 6.3. Scaffold-Based Formats Make A Significant Contribution In The Market
    • 6.3.1. 3D Culture Systems: Distribution By Type of Hydrogels/ECMs
    • 6.3.2. 3D Culture Systems: Distribution By Type of Solid Scaffolds
  • 6.4. 3D Culture Systems: Distribution of Scaffold-Free Systems
    • 6.4.1. 3D Culture Systems: Distribution by Type of Suspension Cultures
    • 6.4.2. 3D Culture Systems: Distribution of Attachment Resistant Culture Surfaces
  • 6.5. 3D Culture System Manufacturers: Regional Outlook
  • 6.6. Other 3D Culture Consumables
  • 6.7. 3D Culture Services

7. 3D CULTURE IN CANCER RESEARCH

  • 7.1. Chapter Overview
  • 7.2. Reasons to Adopt 3D Culture Systems in Cancer Research
  • 7.3. Improving Cancer Drug Screening with 3D Culture System
  • 7.4. 3D Culture Models Used in Oncology
    • 7.4.1. AlgiMatrix, Life Technologies
    • 7.4.2. Cell-Mate3D, BRTI Life Sciences
    • 7.4.3. CELLSTAR Cell-Repellent Surface, Greiner Bio-One International
    • 7.4.4. Elplasia Micro-Space Cell Cultures, Kuraray
    • 7.4.5. Matrigel Matrix, Corning Life Sciences
    • 7.4.6. OncoSpheres, CYTOO
    • 7.4.7. PetakaG3 Cell Culture Devices/Bioreactors, Celartia
    • 7.4.8. QGel, QGel Bio
    • 7.4.9. RAFT System, TAP Biosystems
    • 7.4.10. RealBio D4 Culture System, RealBio Technology

8. 3D CULTURE IN DRUG AND TOXICITY SCREENING

  • 8.1. Chapter Overview
  • 8.2. Drug Screening
  • 8.3. Application of 3D Cultures In Toxicity Studies
    • 8.3.1. Liver As A Key Driver for 3D Innovation
    • 8.3.2. Liver Metabolism
    • 8.3.3. Liver Toxicity: Important Aspect In Toxicology Studies
    • 8.3.4. Liver In Vitro Models
  • 8.4. 3D Cultures Systems Used in Toxicological Studies
    • 8.4.1. 3D Aligned NanoFiber Solutions, Nanofiber Solutions
    • 8.4.2. 3D InSight Human Pancreatic MicroIslets, InSphero
    • 8.4.3. 3D InSight Liver Microtissues, Insphero
    • 8.4.4. 3D Liver Prototissue System, MC2 Biotek
    • 8.4.5. DataChip/MetaChip, Solidus Biosciences
    • 8.4.6. Epiderm Tissue Model, MatTek
    • 8.4.7. exVive3D Liver, Organovo
    • 8.4.8. Gravity PLUS Hanging Drop System, Insphero
    • 8.4.9. LiverChip, CN Bio Innovations Ltd (Formerly Zyoxel Ltd.)
    • 8.4.10. Mimetas OrganoPlates, Mimetas
    • 8.4.11. Multizyme Chip: Multiple Enzyme Chip, Solidus Biosciences
    • 8.4.12. RegeneTOX , Regenemed
    • 8.4.13. TeamChip, Solidus Biosciences

9. 3D CULTURE APPLICATIONS IN STEM CELL RESEARCH

  • 9.1. Chapter Overview
  • 9.2. Potential of 3D Culture Systems in Stem Cell Differentiation
  • 9.3. In Vitro 3D Microenvironment to Induce Embryoid Body Formation
  • 9.4. Organogenesis from Stem Cells
  • 9.5. 3D Culture Systems in Stem Cell Research
    • 9.5.1. AlphaMAX3D ECM, AlphaGenix
    • 9.5.2. Cultrex BME PathClear, Trevigen
    • 9.5.3. Lipidure-COAT Plates, NOF Corporation
    • 9.5.4. MaxGel Human ECM, Sigma Aldrich
    • 9.5.5. Nunclon Sphera, Thermo Fisher Scientific
    • 9.5.6. Perfecta3D Hanging Drop Plates, 3D Biomatrix
    • 9.5.7. PGMatrix, PepGel
    • 9.5.8. PrimeSurface Cell Culture Plate, Sumito Bakelite
    • 9.5.9. StemFit 3D, Prodizen

10. MARKET SIZE AND FORECAST

  • 10.1. Chapter Overview
  • 10.2. Forecast Methodology
  • 10.3. Overall 3D Culture Market, 2015- 2025
  • 10.4. 3D Culture Market Forecast, 2015-2025: Distribution by Components
  • 10.5. 3D Culture Market Forecast, 2015-2025: Geographical Analysis
  • 10.6. 3D Culture Market Forecast, 2015-2025: Distribution by Application
  • 10.7. 3D Culture Market Forecast, 2015-2025: Distribution by Type of 3D System

11. COMPANY PROFILES

  • 11.1. Chapter Overview
  • 11.2. Corning Life Sciences
    • 11.2.1. Company Overview
    • 11.2.2. Financial Details
    • 11.2.3. Product Portfolio
    • 11.2.4. Collaborations
    • 11.2.5. Future Outlook
  • 11.3. Life Technologies
    • 11.3.1. Company Overview
    • 11.3.2. Financial Details
    • 11.3.3. Product Portfolio
    • 11.3.4. Future Outlook
  • 11.4. Sigma Aldrich
    • 11.4.1. Company Overview
    • 11.4.2. Financial Details
    • 11.4.3. Product Portfolio
    • 11.4.4. Future Outlook
  • 11.5. Insphero
    • 11.5.1. Company Overview
    • 11.5.2. Product Portfolio
    • 11.5.3. Collaborations
    • 11.5.4. Future Outlook
  • 11.6. 3D Biotek
    • 11.6.1. Company Overview
    • 11.6.2. Product Portfolio
    • 11.6.3. Collaborations
  • 11.7. Reinnervate
    • 11.7.1. Company Overview
    • 11.7.2. Product Portfolio
    • 11.7.3. Alvetex 3D Culture Scaffold
    • 11.7.4. Collaborations
    • 11.7.5. Future Outlook
  • 11.8. Synthecon
    • 11.8.1. Company Overview
    • 11.8.2. Product Portfolio
    • 11.8.3. Collaborations
    • 11.8.4. Future Outlook
  • 11.9. Neuromics
    • 11.9.1. Company Overview
    • 11.9.2. Product Portfolio
    • 11.9.3. Collaborations
  • 11.10. Cosmo Bio
    • 11.10.1. Company overview
    • 11.10.2. Financial Details
    • 11.10.3. Product Portfolio
    • 11.10.4. Future Outlook

12. CONCLUSION

  • 12.1. 3D Cultures Rapidly Replacing 2D Systems
  • 12.2. 3D Cultures Have Invaded A Myriad Of Applications
  • 12.3. 3D Cultures Yet to Unveil Potential in Therapeutics
  • 12.4. With High Adoption Rates, 3D Cultures Will Emerge As A Multi-Billion Dollar Market

13. INTERVIEW TRANSCRIPTS

14. APPENDIX1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

List of Figures

  • Figure 3.1 Classifications of Cell Cultures
  • Figure 3.2 Various Methods of Cell Isolation from Tissues
  • Figure 3.3 Methods of Cryogenic Storage
  • Figure 3.4 Applications of Cell Culturing
  • Figure 3.5 Cell Culture: Bio-Safety Levels
  • Figure 3.6 Differences in 2D and 3D Cell Cultures
  • Figure 3.7 Key Components of the ECM
  • Figure 3.8 Factors Influencing the Choice of 3D Culture Systems
  • Figure 4.1 Classification of 3D Culture Systems
  • Figure 4.2 Natural Components of ECM
  • Figure 4.3 Advantages and Disadvantages of Hydrogels
  • Figure 6.1 3D Culture Systems: Distribution by Type of System
  • Figure 6.2 3D Culture Systems: Distribution by Sub-Type of Scaffold-Based System
  • Figure 6.3 3D Culture Systems: Distribution by Type of Hydrogels/ECMs
  • Figure 6.4 3D Culture Systems: Distribution of Solid Scaffolds
  • Figure 6.5 3D Culture Systems: Distribution by Sub-Type of Scaffold-Free Systems
  • Figure 6.6 3D Culture Systems: Distribution by Type of Suspension Cultures
  • Figure 6.7 3D Culture Systems: Distribution of Attachment Resistant Culture Surfaces
  • Figure 6.8 3D Culture System Manufacturers: Geographical Distribution of Developers
  • Figure 7.1 Cell-Mate3D: Cell Embedding Process
  • Figure 7.2 Types of Petaka Bioreactors Manufactured by Celartia
  • Figure 7.3 QGel Matrix: Key Features
  • Figure 7.4 QGel Bio: Validated Disease Models
  • Figure 7.5 RAFT Process Simulation
  • Figure 9.1 3D Culture: Effect on Stem Cell Differentiation
  • Figure 9.2 Methods for Embryoid Body Formation
  • Figure 9.3 AlphaMAX3D: Key Advantages
  • Figure 9.4 Lipidure-COAT Plates: Spheroid Formation
  • Figure 9.5 Lipidure-COAT Dishes: Diameter of Embryoid Bodies (in µm)
  • Figure 9.6 MaxGel Human ECM: Procedure for Thin Layer Coating
  • Figure 9.7 Perfecta3D Hanging Drop Culture Plates: Types of Co-Culture Spheroids
  • Figure 9.8 PGMatrix: Key Advantages
  • Figure 10.1 3D Culture Market Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Figure 10.2 3D Culture Market Forecast, 2015-2025: Sub Market Evolution by Components (USD Million)
  • Figure 10.3 3D Culture Market Forecast, 2015-2025: Distribution by Components
  • Figure 10.4 3D Culture Market Forecast, 2015-2025: Geographical Analysis
  • Figure 10.5 3D Culture Market Forecast, 2015-2025: Distribution by Application
  • Figure 10.6 3D Culture Market Forecast, 2015-2025: Distribution by Type of 3D Culture System (USD Million)
  • Figure 11.1 Corning: Revenues by Business Divisions, 2014 (USD Billion)
  • Figure 11.2 Corning Life Sciences: Revenues 2011-2014 (USD Million)
  • Figure 11.3 Life Technologies: Revenues 2010-2013 (USD Billion)
  • Figure 11.4 Sigma-Aldrich: Revenues, 2010-2014 (USD Billion)
  • Figure 11.5 Cosmo Bio: Revenues, 2011 - 2014 (USD Million)
  • Figure 12.1 Cell Behaviour and Signalling: 2D versus 3D Cultures
  • Figure 12.2 3D Culture Market (USD Million), 2015, 2020 and 2025

List of Tables

  • Table 3.1 Morphology of Cells in a Culture
  • Table 4.1 Advantages and Disadvantages of Scaffold-Based and Scaffold-Free Systems
  • Table 4.2 Advantages and Disadvantages of Natural and Synthetic Scaffolds
  • Table 4.3 Advantages and Disadvantages of Natural and Synthetic Hydrogels
  • Table 4.4 Cell Cultures Used in Magnetic Levitation
  • Table 5.1 3D Culture Studies Using Porous Scaffolds
  • Table 5.2 Fabrication of Porous Scaffolds: Merits and Demerits
  • Table 5.3 3D Cell Culture Studies using Fibrous Scaffolds
  • Table 5.4 Fabrication of Fibrous Scaffolds: Merits and Demerits
  • Table 5.5 3D Cell Culture Studies Using Hydrogels
  • Table 5.6 Fabrication of Hydrogels: Merits and Demerits
  • Table 5.7 3D Culture Studies Using Custom Scaffolds
  • Table 5.8 Fabrication of Custom Scaffolds: Merits and Demerits
  • Table 5.9 3D Cell Culture Studies Using Microspheres
  • Table 5.10 Fabrication of Microspheres: Merits and Demerits
  • Table 5.11 3D Cell Culture Studies Using Native Scaffolds
  • Table 5.12 Fabrication of Native Scaffolds: Merits and Demerits
  • Table 6.1 3D Culture System Market Landscape
  • Table 6.2 3D Culture Market Landscape: Assay Kits, Reagents Suppliers
  • Table 6.3 3D Culture Market Landscape: Services
  • Table 7.1 Examples of 3D Culture Systems Used in Cancer Research
  • Table 7.2 Elplasia Micro-Space Cell Culture Plate: Specifications
  • Table 8.1 Examples of 3D Culture Systems Used in Drug and Toxicity Screening
  • Table 8.2 OrganoPlates: Specifications
  • Table 9.1 Example of 3D Culture Systems Used in Stem Cell Research
  • Table 9.2 Product Specification: CultrexBME
  • Table 11.1 Corning Life Science Product Specification: Matrigel Matrices
  • Table 11.2 Corning Life Science Product Specification: Collagen I
  • Table 11.3 Corning Life Sciences Product Specification: ULA Dishes
  • Table 11.4 Corning Life Science Product Specification: ULA Flasks
  • Table 11.5 Life Technologies Product Specification: AlgiMatrix
  • Table 11.6 Life Technologies Product Specification: Collagen I Proteins
  • Table 11.7 Sigma-Aldrich Product Specification: HydroMatrix Hydrogels
  • Table 11.8 Sigma-Aldrich Product Specification: MaxGel ECM
  • Table 11.9 InSphero Product Specification: 3D InSight Liver Microtissues
  • Table 11.10 InSphero Product Specification: 3D InSight Pancreatic Microtissues
  • Table 11.11 InSphero Product Specification: 3D InSight Tumour Microtissues
  • Table 11.12 3D Biotek: Product Dimensions
  • Table 11.13 3D Biotek Product Specification: 3D Insert-PS
  • Table 11.14 3D Biotek Product Specification: 3D Insert PCL
  • Table 11.15 Reinnervate Product Specification: Alvetex 3D Culture Scaffold
  • Table 11.16 Reinnervate: Collaborations
  • Table 11.17 Synthecon Product Specification: Rotary Cell Culture Systems
  • Table 11.18 Synthecon Product Specification: NanobioMatrix Scaffolds
  • Table 11.19 Synthecon Product Specification: Biostructure Matrix Scaffolds
  • Table 11.20 Neuromics Product Specification: CollaGel Hydrogels
  • Table 11.21 Neuromics Product Specification: 3D Nanofiber Solutions
  • Table 11.22 Neuromics Product Specification: AlphaGEL 3D
  • Table 11.23 Neuromics Product Specification :ECM Proteins
  • Table 11.24 Neuromics Product Specification: Petaka Culturing systems
  • Table 11.25 Cosmo Bio Product Specification: Mebiol Gel
  • Table 11.26 Cosmo Bio Product Specifications: Chitosan Coated Cultureware
  • Table 11.27 Cosmo Bio Product Specification: Alginate 3D Cell Culture Kit
  • Table 11.28 Cosmo Bio Product Specification: VECELL 3D Cell Culture Plates
  • Table 11.29 Cosmo Bio Product Specification: Atelocell
  • Table 11.30 Cosmo Bio Product Specification: LIPIDURE-COAT Cultureware
  • Table 14.1 3D Culture Systems: Distribution by Type of System
  • Table 14.2 3D Culture Systems: Distribution by Sub-Type of Scaffold-Based System
  • Table 14.3 3D Culture Systems: Distribution by Type of Hydrogels/ECMs
  • Table 14.4 3D Culture: Distribution of Solid Scaffolds
  • Table 14.5 3D Culture Systems: Distribution by Sub-Type of Scaffold-Free Systems
  • Table 14.6 3D Culture Systems: Distribution by Type of Suspension Cultures
  • Table 14.7 3D Culture: Distribution of Attachment Resistant Culture Surfaces
  • Table 14.8 3D Culture System Manufacturers: Geographical Distribution of Developers
  • Table 14.9 Lipidure-COAT Dishes: Diameter of Embryoid Bodies (in µm)
  • Table 14.10 3D Culture Market Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Table 14.11 3D Culture Market Forecast, 2015 - 2025: Conservative Scenario (USD Million)
  • Table 14.12 3D Culture Market Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
  • Table 14.13 3D Culture Market Forecast, 2015-2025: Sub Market Evolution by Components (USD Million)
  • Table 14.14 3D Culture Market Forecast, 2015-2025: Distribution by Components
  • Table 14.15 3D Culture Market Forecast, 2015-2025: Geographical Analysis
  • Table 14.16 3D Culture Market Forecast, 2015-2025: Distribution by Application
  • Table 14.17 3D Culture Market Forecast, 2015-2025: Distribution by Type of 3D System (USD Million)
  • Table 14.18 Corning: Revenues by Business Divisions, 2014 (USD Billion)
  • Table 14.19 Corning Life Sciences: Revenues 2011-14 (USD Million)
  • Table 14.20 Life Technologies: Revenues 2010-2013 (USD Billion)
  • Table 14.21 Sigma-Aldrich: Revenues, 2010-14 (USD Billion)
  • Table 14.22 Cosmo Bio: Revenues, 2011 - 2014 (USD Million)
  • Table 14.23 3D Culture Market (USD Million), 2015, 2020 and 2025

Listed Companies

The following companies and institutes have been mentioned in this report.

  • 1. 3D Biomatrix
  • 2. 3D Biotek, LLC
  • 3. 4titude
  • 4. Abbvie
  • 5. Agilent
  • 6. Akron Biotechnology, LLC
  • 7. Alphagenix
  • 8. AMS Bio
  • 9. AstraZeneca Pharmaceuticals
  • 10. Austrianova
  • 11. Avanticell Science
  • 12. BASF
  • 13. BD Bioscience
  • 14. BellBrook Labs
  • 15. Bethesda Research Laboratories
  • 16. Bio Connect
  • 17. Bio-Byblos Biomedical Co. Ltd.
  • 18. BioCellChallenge
  • 19. Biogelx Ltd.
  • 20. Biomerix
  • 21. Biozol GmbH
  • 22. BRTI Life Sciences
  • 23. Celartia
  • 24. Celenys SAS
  • 25. CellecBiotek AG
  • 26. Cellendes GmbH
  • 27. ChemieBrunschwig AG
  • 28. Cleveland Clinic
  • 29. Clontech
  • 30. CN Bio Innovations Ltd.
  • 31. Corning Life Sciences
  • 32. Cosmo Bio Co. Ltd.
  • 33. Cytoo
  • 34. Dexter Corporation
  • 35. Durham University
  • 36. EMD Millipore
  • 37. Emulate Inc.
  • 38. ESI Bio
  • 39. Euroclone
  • 40. European Union's Seventh Framework Programme (FP7) for Research and Technology Development
  • 41. Factors Technical University Dortmund
  • 42. FMC BioPolymer AS
  • 43. Fujifilm
  • 44. GE Healthcare
  • 45. GeneON GmbH
  • 46. Generon
  • 47. GIBCO Corporation
  • 48. GlaxoSmithKline
  • 49. Global Cell Solutions
  • 50. GlycosanBioSystems
  • 51. Greiner Bio-one
  • 52. Hµrel Corporation
  • 53. Hamilton Company
  • 54. Heidelberg University Hospital
  • 55. Hepregen Corp
  • 56. Hokkaido Soda
  • 57. In Vitro AS
  • 58. Insphero
  • 59. Instron
  • 60. Invivo Sciences
  • 61. Iris Biosciences
  • 62. Japan Vilene Company
  • 63. Karolinska Institute
  • 64. Kirkstall
  • 65. Kiyatec
  • 66. Koken Co. Ltd.
  • 67. Kolloidis Biosciences
  • 68. Kuraray Co., Ltd.
  • 69. Leibniz Research Centre For Working Environment and Human
  • 70. Lena Biosciences
  • 71. Life Technologies
  • 72. Lifecore Biomedical,
  • 73. Locate Therapeutics
  • 74. LuoLabs
  • 75. Massachusetts General Hospital
  • 76. MatTek Corporation
  • 77. MC2 Biotek
  • 78. Mebiol Inc.
  • 79. Medicyte
  • 80. Menicon Life Science
  • 81. Merck
  • 82. MicroTissues Inc.
  • 83. Mimetas B.V.
  • 84. Mirus Bio
  • 85. n3D Biosciences, Inc.
  • 86. Nanofiber Solutions
  • 87. NASA
  • 88. National Cancer Institute
  • 89. National Institute of Health
  • 90. National Institute of Standards and Technology
  • 91. NC3Rs
  • 92. Neuromics
  • 93. NOF Corporation
  • 94. Oncotest GmbH
  • 95. Organovo Holdings Inc.
  • 96. ParticipatiemaatschapijOost Nederland
  • 97. PepGel LLC
  • 98. Pfizer
  • 99. Prodizen
  • 100. Promega
  • 101. Protea Biosciences
  • 102. Protista International AB
  • 103. QGel Bio
  • 104. Radboudumc Pharmacology
  • 105. RealBio Technology Inc.
  • 106. Reinnervate
  • 107. Roche
  • 108. RoslinCellab
  • 109. Sanofi
  • 110. SBH Sciences
  • 111. Scivax Life Sciences
  • 112. Sigma Aldrich
  • 113. Solidus Biosciences, Inc.
  • 114. SoloHill
  • 115. Stemcell Technologies
  • 116. Sumitomo Bakelite Co. Ltd.
  • 117. Swiss Federal Institute of Technology
  • 118. Swiss FHNW
  • 119. Synthecon Incorporated
  • 120. SynVivo LLC
  • 121. TAP Biosystems
  • 122. Tecan
  • 123. Thermo Scientific
  • 124. Tianjin WeikaiBioeng Ltd.
  • 125. Trevigen
  • 126. Univalor
  • 127. University College London
  • 128. University of Illinois
  • 129. University of Liverpool
  • 130. University of Reading
  • 131. University of Utrecht
  • 132. University Zurich
  • 133. UPM
  • 134. VesselxIKKO-ZU
  • 135. VistaGen Therapeutics
  • 136. Vivo Biosciences
  • 137. WiCell Research Institute
  • 138. Wyss Institute, Harvard University
  • 139. ZeeuwsInvesteringsFonds
  • 140. Zyoxel
Back to Top